P3 Health Partners Inc. Form 8-K Summary
Business Context and Reporting Period
On December 3, 2021, formerly named Foresight Acquisition Corp., the Company completed its business combination with P3 Health Group Holdings, LLC. P3 Health Partners Inc. became the public holding company for P3 Health Group, LLC and its operating subsidiaries in an Up-C structure. The Company initially owned approximately 17.1% of P3 LLC and became its sole manager. P3’s Class A common stock and warrants began trading on Nasdaq under the symbols PIII and PIIIW on December 6, 2021.
The filing includes historical P3 financial information for the years ended December 31, 2019 and 2020 and unaudited nine-month periods ended September 30, 2020 and 2021. The pre-combination Foresight entity was a shell company with no operations.
Financial Metrics
| Metric | Nine months ended September 30, 2021 | Nine months ended September 30, 2020 | Change |
|---|---|---|---|
| Total revenues | $459.5 million | $360.7 million | 27.4% increase |
| Capitated revenue | $447.1 million | $351.0 million | 27.4% increase |
| Other patient service revenue | $12.4 million | $9.6 million | 28.2% increase |
| Total operating expenses | $520.1 million | $385.0 million | 35.1% increase |
| Loss from operations | $(60.6) million | $(24.3) million | Loss increased |
| Net loss | $(85.7) million | $(31.2) million | Loss increased |
| Net loss attributable to controlling interests | $(77.8) million | $(27.7) million | Loss increased |
| Adjusted EBITDA | $(52.4) million | $(24.3) million | Loss increased |
Revenue increased materially, but operating expenses grew faster than revenue. Medical expense was $459.2 million, and the Company recorded a $4.6 million premium deficiency reserve in the 2021 period versus a $1.3 million benefit in the comparable 2020 period. The 2021 net loss also included $12.1 million of mark-to-market warrant expense and $0.9 million of business-combination transaction expense.
As of September 30, 2021, cash and restricted cash were $4.7 million, health plan settlement receivables were $45.8 million, working capital was negative $64.8 million, total assets were $78.5 million, long-term debt excluding the current portion was $59.4 million, and total members’ deficit was $179.2 million. The filing does not provide a clear consolidated cash-flow value in the summarized text.
Debt, Liquidity, and Capitalization
P3 had a term loan facility with aggregate principal capacity of up to $100.0 million, of which $52.8 million had been drawn as of September 30, 2021. An additional $47.2 million was available at that date, subject to draw deadlines. The loan matures on December 31, 2025, bears interest at 12.0% annually, and permits 8.0% cash interest plus 4.0% PIK interest for a three-year period. P3 had elected the PIK structure beginning in March 2021.
The facility requires minimum liquidity of $5.0 million and specified annual revenue levels, including $395.0 million for 2021 and $460.0 million for 2022. P3 fell below the minimum liquidity covenant on certain days in September 2021 and obtained a waiver. The loan is secured by substantially all assets of P3 and its subsidiary guarantors and restricts additional indebtedness, liens, restricted payments, and dividends.
At closing, the Company issued 20,370,307 PIPE shares at $10.00 per share for aggregate gross proceeds of approximately $203.7 million. Following the transaction, approximately 41.6 million Class A shares and 202.0 million Class V shares were outstanding, along with 10.8 million warrants.
Material Changes Versus the Prior Comparable Period
- Revenue increased 27.4% for the nine months ended September 30, 2021, while total operating expenses increased 35.1%.
- Operating loss widened from $24.3 million to $60.6 million, and net loss widened from $31.2 million to $85.7 million.
- Adjusted EBITDA loss increased from $24.3 million to $52.4 million.
- Medical expense increased to $459.2 million from $348.3 million, and the premium deficiency reserve changed from a $1.3 million benefit to a $4.6 million expense.
- The Company completed the business combination, changed its name, adopted an amended charter and bylaws, and changed its board and executive leadership.
- Sherif Abdou became Chief Executive Officer, Amir Bacchus became Chief Medical Officer, and Eric Atkins became Chief Financial Officer. Michael Balkin and Gerald Muizelaar departed as CEO and CFO, respectively.
- BDO USA, LLP was engaged as the Company’s independent registered public accounting firm, replacing Marcum LLP for Foresight and KPMG LLP for P3.
Guidance, Outlook, Risks, and Unusual Items
The filing does not provide formal operating guidance or a detailed management forecast. The debt agreement contains minimum annual consolidated revenue requirements of $395.0 million for 2021, $460.0 million for 2022, $525.0 million for 2023, $585.0 million for 2024, and $650.0 million for 2025.
Material risks include the Company’s ability to maintain Nasdaq listing, satisfy the 300-round-lot-holder requirement, realize anticipated business-combination benefits, manage growth profitably, comply with debt covenants, and fund operations despite negative working capital and continuing losses. Nasdaq notified the Company that it had not demonstrated compliance with the round-lot-holder requirement and that its warrants did not qualify for initial listing because the underlying Class A common stock did not qualify. The Company appealed, which stayed suspension of the securities pending a Nasdaq Hearings Panel decision; no assurance was given that compliance would be achieved.
Certain merger consideration was placed in escrow pending resolution of the Class D Dispute and Cash Preference Dispute. The filing also identifies material weaknesses involving complex financial instruments at Foresight and P3’s accounting controls, including controls over health expense reserves, premium deficiency reserves, business combinations, equity awards, and journal-entry processing.
The Company has not paid dividends and stated that it does not anticipate declaring dividends in the foreseeable future. Debt covenants also restrict P3 LLC’s ability to pay dividends to the Company.
Important Facts for Investors to Verify
- Review the final audited financial statements and subsequent filings for updated revenue, losses, cash flows, liquidity, and debt balances.
- Confirm whether P3 satisfied the $5.0 million minimum liquidity covenant and the applicable annual revenue covenant, and monitor any additional waivers or defaults.
- Track the Nasdaq appeal and whether the Company ultimately satisfied the round-lot-holder requirement and maintained listing of its common stock and warrants.
- Assess the impact of the Class D Dispute and Cash Preference Dispute on escrowed cash, P3 LLC units, Class V shares, and Class A shares.
- Review the term loan’s cash and PIK interest burden, collateral package, maturity, and restrictions on distributions.
- Evaluate the identified material weaknesses and the effectiveness of remediation efforts under the new auditor, BDO.
- Reconcile the pro forma ownership structure, potential warrant dilution, PIPE shares, and the 2021 incentive plan share reserve.
- Review subsequent SEC filings for updated management projections, operating performance, regulatory developments, and litigation outcomes.